

## Company Announcement

13 September 2010

## Novo Nordisk A/S – Share repurchase programme

On 12 August 2010 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 1.0 billion in the period from 12 August 2010 to 25 October 2010.

Since the announcement as of 6 September 2010, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last	595,000		296,658,933
announcement			
06 September 2010	35,000	506.4000	17,724,000
07 September 2010	35,000	513.7100	17,979,850
08 September 2010	35,000	514.7600	18,016,600
09 September 2010	35,000	527.3700	18,457,950
10 September 2010	35,000	541.8300	18,964,050
Accumulated under	770,000		387,801,383
the programme	•		

With the transactions stated above, Novo Nordisk owns a total of 25,648,087 treasury shares, corresponding to 4.3% of the share capital. The total amount of shares in the company is 600,000,000 including treasury shares.

Company Announcement no 51 / 2010

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Telefax: +45 4444 6626 Internet: novonordisk.com CVR no:

CVR no: 24256790

Page 1 of 2

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 29,890 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit <u>novonordisk.com</u>.

## Further information:

Media:

Anne Margrethe Hauge Tel: (+45) 4442 3450 amhg@novonordisk.com Investors:

Klaus Bülow Davidsen Tel: (+45) 4442 3176 klda@novonordisk.com

Kasper Roseeuw Poulsen Tel: (+45) 4442 4471 krop@novonordisk.com

Jannick Lindegaard Tel: (+45) 4442 4765 jlis@novonordisk.com

In North America: Lori Moore Tel: (+1) 609 919 7991 Irmo@novonordisk.com In North America: Hans Rommer Tel: (+1) 609 919 7937 hrmm@novonordisk.com

Company Announcement no 51 / 2010

Novo Nordisk A/S Investor Relations Novo Allé 2880 Bagsværd Denmark Telephone: +45 4444 8888 Telefax: +45 4444 6626 Internet: novonordisk.com CVR no: 24256790

Page 2 of 2